Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
Investigators report that lifestyle interventions during pregnancy reduce gestational diabetes risk, with effects varying by diagnostic criteria and maternal education level.